User profiles for Shelby Barnett
Shelby BarnettNewcastle University Verified email at newcastle.ac.uk Cited by 276 |
Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B‐mediated drug–drug interactions using population pharmacokinetic …
S Barnett, K Ogungbenro, K Ménochet… - Clinical …, 2018 - Wiley Online Library
This study evaluated coproporphyrin I (CPI) as a selective endogenous biomarker of
OATP1B‐mediated drug–drug interactions (DDIs) relative to clinical probe rosuvastatin using …
OATP1B‐mediated drug–drug interactions (DDIs) relative to clinical probe rosuvastatin using …
[HTML][HTML] Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients
S Barnett, F Hellmann, E Parke, G Makin… - European Journal of …, 2022 - Elsevier
Background The anticancer drug vincristine is associated with potentially dose-limiting side-effects,
including neurotoxicity and myelosuppression. However, there currently exists a lack …
including neurotoxicity and myelosuppression. However, there currently exists a lack …
Comprehensive evaluation of the utility of 20 endogenous molecules as biomarkers of OATP1B inhibition compared with rosuvastatin and coproporphyrin I
S Barnett, K Ogungbenro, K Menochet, H Shen… - … of Pharmacology and …, 2019 - ASPET
Endogenous biomarkers can be clinically relevant tools for the assessment of transporter
function in vivo and corresponding drug-drug interactions (DDIs). The aim of this study was to …
function in vivo and corresponding drug-drug interactions (DDIs). The aim of this study was to …
PBPK model of coproporphyrin I: evaluation of the impact of SLCO1B1 genotype, ethnicity, and sex on its inter‐individual variability
H Takita, S Barnett, Y Zhang… - CPT …, 2021 - Wiley Online Library
Coproporphyrin I (CPI) is an endogenous biomarker of OATP1B activity and associated drug‐drug
interactions. In this study, a minimal physiologically‐based pharmacokinetic model …
interactions. In this study, a minimal physiologically‐based pharmacokinetic model …
[HTML][HTML] In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems
SL Beedie, HM Rore, S Barnett, CH Chau, W Luo… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Thalidomide, a drug known for its teratogenic side-effects, is used successfully to treat a
variety of clinical conditions including leprosy and multiple myeloma. Intense efforts are …
variety of clinical conditions including leprosy and multiple myeloma. Intense efforts are …
[HTML][HTML] Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance
AL Nijstad, S Barnett, A Lalmohamed… - European Journal of …, 2022 - Elsevier
Cancer in neonates and infants is a rare but challenging entity. Treatment is complicated by
marked physiological changes during the first year of life, excess rates of toxicity, mortality, …
marked physiological changes during the first year of life, excess rates of toxicity, mortality, …
[HTML][HTML] Generation of evidence-based carboplatin dosing guidelines for neonates and infants
S Barnett, G Makin, DA Tweddle, C Osborne… - British Journal of …, 2023 - nature.com
Background To optimally dose childhood cancer patients it is essential that we apply
evidence-based dosing approaches. Carboplatin is commonly dosed to achieve a cumulative …
evidence-based dosing approaches. Carboplatin is commonly dosed to achieve a cumulative …
[HTML][HTML] A population pharmacokinetic modelling approach to unravel the complex pharmacokinetics of vincristine in children
…, ME van de Velde, GJL Kaspers, S Barnett… - Pharmaceutical …, 2022 - Springer
Background Vincristine, a chemotherapeutic agent that extensively binds to β-tubulin, is
commonly dosed at 1.4–2.0 mg/m 2 capped at 2 mg. For infants, doses vary from 0.025–0.05 mg/…
commonly dosed at 1.4–2.0 mg/m 2 capped at 2 mg. For infants, doses vary from 0.025–0.05 mg/…
[HTML][HTML] Perspectives and expertise in establishing a therapeutic drug monitoring programme for challenging childhood cancer patient populations
S Barnett, V Holden, Q Campbell-Hewson… - Frontiers in …, 2022 - frontiersin.org
The utility of Therapeutic Drug Monitoring (TDM) in the setting of childhood cancer is a
largely underused tool, despite the fact that treatment commonly involves administration of …
largely underused tool, despite the fact that treatment commonly involves administration of …
Anticancer properties of a novel class of tetrafluorinated thalidomide analogues
Thalidomide has demonstrated clinical activity in various malignancies affecting
immunomodulatory and angiogenic pathways. The development of novel thalidomide analogs with …
immunomodulatory and angiogenic pathways. The development of novel thalidomide analogs with …